Clinical Trials in San Antonio

Showing 4721-4740 of 11,125 trials

A Phase II Study of RBM-007 Alone and RBM-007 With Eylea® in Subjects With Wet Age-related Macular Degeneration

NCT04200248

This is a multicenter, active-controlled, double masked study assessing the safety, efficacy and durability of four monthly intravitreal (IVT) injections of RBM-007 monotherapy, and four monthly RBM-007 injections in combination with Eylea® dosed at every other month, compared to Eylea® monotherapy dosed at every other month in approximately eighty-one subjects with exudative age-related macular degeneration (AMD).

Exudative Age-related Macular Degeneration

Ribomic USA Inc94 participantsStarted Dec 2019

Phoenix, Arizona, United States • Sacramento, California, United States • Walnut Creek, California, United States +5 more locations

TERMINATEDPhase 2< 1 mile

Study to Evaluate the Efficacy and Safety of CC-90001 in Participants With Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis

NCT04048876

This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter, multinational, dose-finding study evaluating the efficacy of three treatment doses of CC-90001 compared with placebo, in Non-alcoholic Steatohepatitis (NASH) participants with Stage 2, Stage 3 liver fibrosis. This study is designed to assess response to treatment on measures of fibrosis and other efficacy parameters. It will also assess dose response and overall safety.

Non-alcoholic Fatty Liver DiseaseLiver Cirrhosis

Celgene56 participantsStarted Aug 2019

Phoenix, Arizona, United States • Phoenix, Arizona, United States • La Jolla, California, United States +139 more locations

A Phase II Study of RBM-007 Alone and RBM-007 With Eylea® in Subjects With Wet Age-related Macular Degeneration

Study to Evaluate the Efficacy and Safety of CC-90001 in Participants With Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis

Find Trials by Condition in San Antonio

Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma

A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder

Safety and Exploratory Efficacy Study of SF0166 in the Treatment of Neovascular Age-Related Macular Degeneration (AMD)

Clinical Outcome Assessment of Parkinson's Disease Patients Treated With XADAGO (Safinamide)

Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma

Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis

International Hernia Mesh Registry

Pharmacokinetics and Safety of Ceftobiprole in Neonates and Infants up to 3 Months Treated With Systemic Antibiotics

Convalescent Plasma to Limit SARS-CoV-2 Associated Complications

A Randomized, Controlled Trial of Ganaxolone in Patients With Infantile Spasms

Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors

Single-Ascending Dose Study of JK07 in Subjects With HFpEF

Study of Diroximel Fumarate in the Real-World Setting

Rate of Atrial Fibrillation Through 12 Months in Patients With Recent Ischemic Stroke of Presumed Known Origin

Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus Host Disease (aGVHD) in Participants Undergoing Allogeneic Hematopoietic Stem Cell (Allo-HSCT) Transplantation

A Phase 4 Study of Efficacy and Safety of Apremilast in Subjects With Moderate Plaque Psoriasis.

An Open-label Study of ALPN-202 in Subjects With Advanced Malignancies

An Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients With Non-Gorlin High Frequency BCC